Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Up to $10.57

Centessa Pharmaceuticals plc (NASDAQ:CNTA)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $10.57, but opened at $10.90. Centessa Pharmaceuticals shares last traded at $10.33, with a volume of 63,748 shares trading hands.

Analyst Ratings Changes

Separately, BMO Capital Markets reiterated an “outperform” rating and set a $15.00 price target on shares of Centessa Pharmaceuticals in a report on Monday, April 1st. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $10.00.

Centessa Pharmaceuticals Trading Down 6.0 %

The firm has a market capitalization of $942.91 million, a PE ratio of -5.99 and a beta of 1.38. The company has a current ratio of 8.00, a quick ratio of 8.00 and a debt-to-equity ratio of 0.32. The business has a fifty day moving average price of $10.95 and a two-hundred day moving average price of $8.50.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Thursday, March 28th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. The business had revenue of $6.85 million for the quarter. Analysts expect that Centessa Pharmaceuticals plc will post -1.83 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Karen M. Anderson sold 51,160 shares of the stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $11.88, for a total transaction of $607,780.80. Following the transaction, the insider now owns 71,525 shares of the company’s stock, valued at approximately $849,717. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, insider Karen M. Anderson sold 51,160 shares of the stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $11.88, for a total transaction of $607,780.80. Following the transaction, the insider now owns 71,525 shares of the company’s stock, valued at approximately $849,717. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Harris Rotman sold 4,267 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $8.10, for a total value of $34,562.70. Following the transaction, the senior vice president now directly owns 62,625 shares in the company, valued at approximately $507,262.50. The disclosure for this sale can be found here. 11.54% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of hedge funds have recently bought and sold shares of CNTA. TD Asset Management Inc raised its position in Centessa Pharmaceuticals by 127.1% in the 3rd quarter. TD Asset Management Inc now owns 186,310 shares of the company’s stock valued at $1,205,000 after purchasing an additional 104,255 shares in the last quarter. Platinum Investment Management Ltd. raised its position in Centessa Pharmaceuticals by 96.7% in the 3rd quarter. Platinum Investment Management Ltd. now owns 337,544 shares of the company’s stock valued at $2,184,000 after purchasing an additional 165,919 shares in the last quarter. Rathbones Group PLC acquired a new stake in Centessa Pharmaceuticals in the 3rd quarter valued at about $203,000. Affinity Asset Advisors LLC raised its position in Centessa Pharmaceuticals by 13.0% in the 3rd quarter. Affinity Asset Advisors LLC now owns 1,018,091 shares of the company’s stock valued at $6,587,000 after purchasing an additional 117,368 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its position in Centessa Pharmaceuticals by 25.8% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 2,830,500 shares of the company’s stock valued at $18,313,000 after purchasing an additional 580,500 shares in the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.